2/22/2006

Golden exclusivity

Filed under: — Licenblog @ 9:36 am on


After Japan, the Pravastatin - the revolutionary drug for hyperlididemia is moving to the generic realm in US as well.

Licenblog is a joint blog - post or send comments to licenblog@licenscape.com

Comments (0)

2/17/2006

The end of Pravastatin age

Filed under: — Licenblog @ 9:38 am on


The following enigmatic announcement has been posted at the web site of Daiichi Sankyo on February 17, 2006. Neither BMS nor Watson has any references for the announcement.

Future Business Prospects of the Hyperlipidemia Drug Pravastatin in the United States

Tokyo, February 17, 2006 - DAIICHI SANKYO COMPANY, LIMITED has announced today that the exclusive sales period for the hyperlipidemia drug Pravachol® (Japanese brand name: Mevalotin®), that is supplied by its subsidiary Sankyo Co., Ltd. (President: Yasuhiro Ikegami; hereafter Sankyo) to Bristol-Myers Squibb Company (hereafter BMS), in the United States is coming to an end as of April 20, 2006, and an agreement has been reached between BMS and Watson Pharmaceuticals, Inc. for the sale of generic versions of Pravachol® within the United States. Sankyo is supplying the active constituent for pravastatin to BMS, which is in turn selling it in the United States and throughout the world. Sankyo will continue to supply the active constituent of pravastatin through BMS.

Licenblog is a joint blog - post or send comments to licenblog@licenscape.com

Comments (0)